[{
		"name": "BLING2",
		"description": "A Multicenter Randomized Trial of Continuous versus Intermittent Î²-Lactam Infusion in Severe Sepsis",
		"img": "https://www.thebottomline.org.uk/wp-content/uploads/2015/07/BLING2.png"
	},
	{
		"name": "Clinical Question",
		"description": "In adult ICU patients on beta-lactam antibiotics, does continuous infusion compared to intermittent bolus increase survival?",
		"img": "https://www.thebottomline.org.uk/wp-content/uploads/2015/07/BLING2.png"
	}, {
		"name": "Design",
		"description": "Randomised, controlled trial
                     Double-blind with double-dummy preparations
                     Unblinded staff prepared drugs and consecutively labelled sealed opaque envelopes
                     Study participants, clinicians and data investigators remained blinded
                     Pilot trial conducted to guide power calculation
                      Sample size of 420 required to achieve 90% power to detect a 3 day difference in the primary outcome
                      Intention-to-treat (ITT) analysis for primary end points, in addition to:
                      Modified intention-to-treat (mITT) conducted in eligible patients who received a study drug
                      A priori per protocol analysis in those who received 3 or more days of a study drug",
		"img": "https://www.thebottomline.org.uk/wp-content/uploads/2015/07/BLING2.png"
	}, {
		"name": "Setting",
		"description": "25 Intensive Care Units (17 in Australia, 7 in New Zealand and 1 in Hong Kong)
                    July 2012 to April 2014",
		"img": "https://www.thebottomline.org.uk/wp-content/uploads/2015/07/BLING2.png"
	}, {
		"name": "Population",
		"description": "Inclusion: adults with severe sepsis commenced on any of:
                    Piperacillin-tazobactam
                    Ticarcillin-clavulanate
                    Meropenem
                     Exclusion:
                    Received beta-lactam for more than 24 hours duration prior to randomisation
                      Pregnancy
                    Allergy to study drugs
                      No central venous line with >= 3 lumens
                    Palliative treatment only, limits to care, death is imminent or death is likely within 90 days due to underlying process
                    2630 patients screened, 432 eligible patients were randomised (ITT), 422 received a study drug (mITT)
                    Pathogen isolated in blood cultures in 83 patients",
		"img": "https://www.thebottomline.org.uk/wp-content/uploads/2015/07/BLING2.png"
	},{
		"name": "Intervention",
		"description": "Continuous infusion of beta-lactam antibiotics
                     Loading dose of chosen antibiotic
                     Continuous infusion thereafter
                      1g in 100ml Meropenem over 24 hours
                      13.5g in 250ml Piperacillin-tazobactam over 24 hours
                      12.4g in 250ml Ticarcillin-clavulanate over 24 hours
                      Administered with a normal saline dummy intermittent infusion",
		"img": "http://1.bp.blogspot.com/-bxRUoPcWD88/Vg3wy0oKMbI/AAAAAAAAEHY/jo-X45aplTc/s640/tbl-datasheet-bling2.png"
	}
]
